Vertex Pharmaceuticals Management
Management criteria checks 3/4
Vertex Pharmaceuticals' CEO is Reshma Kewalramani, appointed in Apr 2020, has a tenure of 5.67 years. total yearly compensation is $21.54M, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 0.046% of the company’s shares, worth $53.70M. The average tenure of the management team and the board of directors is 6.8 years and 5.8 years respectively.
Key information
Reshma Kewalramani
Chief executive officer
US$21.5m
Total compensation
| CEO salary percentage | 7.16% |
| CEO tenure | 5.7yrs |
| CEO ownership | 0.05% |
| Management average tenure | 6.8yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
Vertex Pharmaceuticals' (NASDAQ:VRTX) Performance Is Even Better Than Its Earnings Suggest
Nov 11
Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings
Oct 28Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Popularity With Investors Is Under Threat From Overpricing
Sep 19New ALYFTREK And JOURNAVX Will Expand Patient Access
Vertex is set to drive revenue growth by expanding its drug portfolio, notably with ALYFTREK and JOURNAVX, targeting new patient demographics.Vertex Pharmaceuticals: A Look At Their Pain Therapy Program
Apr 06Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Mar 06Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Jan 31Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine
Jan 14Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Dec 31Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
Dec 11Vertex Pharma: Why I Am Buying This Dip
Nov 25Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Nov 05Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
Oct 18Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)
Oct 10Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug
Sep 15Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced
Sep 05Vertex Stock: Came For CF Drugs, Staying For Gene Therapy
Aug 02Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Jul 09Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales
Jun 17Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Jun 04Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$4b |
| Jun 30 2025 | n/a | n/a | US$4b |
| Mar 31 2025 | n/a | n/a | -US$989m |
| Dec 31 2024 | US$22m | US$2m | -US$536m |
| Sep 30 2024 | n/a | n/a | -US$480m |
| Jun 30 2024 | n/a | n/a | -US$490m |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$21m | US$2m | US$4b |
| Sep 30 2023 | n/a | n/a | US$3b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$3b |
| Dec 31 2022 | US$16m | US$1m | US$3b |
| Sep 30 2022 | n/a | n/a | US$3b |
| Jun 30 2022 | n/a | n/a | US$3b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$15m | US$1m | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$3b |
| Dec 31 2020 | US$9m | US$1m | US$3b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$7m | US$702k | US$1b |
Compensation vs Market: Reshma's total compensation ($USD21.54M) is above average for companies of similar size in the US market ($USD13.36M).
Compensation vs Earnings: Reshma's compensation has been consistent with company performance over the past year.
CEO
Reshma Kewalramani (52 yo)
Dr. Reshma Kewalramani, M.D., FASN, was Director at Year Up Inc. since September 2023. She had been an Independent Director of Ginkgo Bioworks Holdings, Inc. (formerly known as Ginkgo Bioworks, Inc.) since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 16.4yrs | US$6.57m | 0.0096% $ 11.3m | |
| CEO, President & Director | 5.7yrs | US$21.54m | 0.046% $ 53.7m | |
| Executive VP | 6.7yrs | US$8.00m | 0.0060% $ 7.1m | |
| Executive VP & Chief Scientific Officer | 10.9yrs | US$7.64m | 0.0092% $ 10.8m | |
| Executive VP and Chief Regulatory & Quality Officer | 8.3yrs | US$7.33m | 0.010% $ 12.0m | |
| Senior VP & Chief Accounting Officer | 4.6yrs | no data | 0.0031% $ 3.6m | |
| Senior Vice President of Investor Relations | 3.3yrs | no data | no data | |
| Executive VP & Chief Legal Officer | 3.3yrs | no data | 0.0060% $ 7.1m | |
| Senior VP & Chief Communications Officer | 6.9yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | 8.3yrs | no data | no data | |
| Executive VP & Chief Patient and External Affairs Officer | 18.4yrs | US$6.20m | 0.027% $ 32.1m | |
| Senior VP & Head of Research | 9.9yrs | no data | no data |
Experienced Management: VRTX's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 16.4yrs | US$6.57m | 0.0096% $ 11.3m | |
| CEO, President & Director | 5.8yrs | US$21.54m | 0.046% $ 53.7m | |
| Lead Independent Director | 27.9yrs | US$603.19k | 0.018% $ 20.8m | |
| Independent Director | 8.5yrs | US$521.86k | 0.0026% $ 3.0m | |
| Independent Director | 6.8yrs | US$564.18k | 0.0022% $ 2.6m | |
| Independent Director | 10.5yrs | US$550.11k | 0.0015% $ 1.8m | |
| Independent Director | 2.2yrs | US$538.52k | 0.00045% $ 528.6k | |
| Independent Director | 5.5yrs | US$549.96k | 0.00065% $ 763.6k | |
| Independent Director | 3.6yrs | US$562.97k | 0.00061% $ 716.6k | |
| Independent Director | 2yrs | US$519.27k | 0.00065% $ 763.6k | |
| Independent Director | 1.6yrs | US$495.87k | 0% $ 0 |
Experienced Board: VRTX's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 11:28 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vertex Pharmaceuticals Incorporated is covered by 64 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Huidong Wang | Barclays |